共 26 条
[1]
Zeldis JB(2011)A review of the history, properties, and use of the immunomodulatory compound lenalidomide Ann N Y Acad Sci 1222 76-82
[2]
Knight R(2013)Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma Leuk Lymphoma 54 683-687
[3]
Hussein M(2014)Approaches to managing safety with lenalidomide in hematologic malignancies J Adv Pract Oncol 5 269-279
[4]
Chopra R(2012)Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity Cancer Chemother Pharmacol 70 717-725
[5]
Muller G(2012)Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects Cancer Chemother Pharmacol 69 789-797
[6]
Zhu YX(2017)Clinical pharmacokinetics and pharmacodynamics of lenalidomide Clin Pharmacokinet 56 139-152
[7]
Kortuem KM(2013)Lenalidomide at therapeutic and supratherapeutic doses does not prolong QTc intervals in the thorough QTc study conducted in healthy men Basic Clin Pharmacol Toxicol 113 179-186
[8]
Stewart AK(undefined)undefined undefined undefined undefined-undefined
[9]
Blumel S(undefined)undefined undefined undefined undefined-undefined
[10]
Broadway-Duren J(undefined)undefined undefined undefined undefined-undefined